Recently, two Malaria Box molecules namely MMV007571 and MMV020439 well known inhibitors of New Permeability Pathway (NPP) function also showed a secondary phenotype of inhibition of enzyme Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) and cytochrome bc1 complex in metabolic profile assays. Intricacies of their binding at the newly identified targets was need of the hour which motivated us to study their binding using molecular docking and dynamics simulations approach. Interestingly, molecular docking results of both MMV007571 and MMV020439 showed good binding affinity toward the Qo site of cytochrome bc1 complex while only MMV007571 illustrated notable binding characterstics for PfDHODH. Molecular Dynamics (MD) simulations when carried out for native-PfDHODH, PfDHODH-MMV007571 and PfDHODH-Genz667348 models (100 ns each) demonstrated the role of inhibitors over the N-terminus domain which experienced conformational transition from an open state (22 Å) to closed state (16 Å) in the protein-inhibitor models. Dynamics also indicated that the loop domain near cofactor flavin mononucleotide (FMN) attained more felxibility which further lead to its poor binding and may contribute to inhibition of the oxidation (catalytic) process. Moreover, the pharmacophoric features of MMV007571 was justified and may serve as a template for the design of novel series of more potent multitarget inhibitors against Plasmodium falciparum.
Abbreviations
ÅAngstrom
ACTsArtemisinin combination therapies
cyt bc1cytochrome bc1 complex
hhour(s)
KKelvin
µMmicromolar
MMVMedicine for malaria venture
NLucNanoluciferase
nMnanomolar
NPPNew permeation pathway
PDBProtein data bank
PfDHODHPlasmodium falciparum dihydroorotate dehydrogenase
POPC1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
RBCRed blood corpuscles
RMSDRoot-mean-square deviation
SPStandard precision
vdWvan der Waals
XPExtra precision
yDHODHYeast dihydroorotate dehydrogenase
Communicated by Ramaswamy H. Sarma